PROCEPT INC
4, 1997-09-10
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: NYER MEDICAL GROUP INC, 10QSB/A, 1997-09-10
Next: PROCEPT INC, 4, 1997-09-10



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
( ) Check this box if no longer subject to Section 16.
Form 4 or Form 5 obligations may continue. See Instructions 1(b).
1. Name and Address of Reporting Person
   The Aries Trust
   c/o Paramount Capital Asset Management, Inc.
   787 Seventh Avenue - 48th Floor
   New York, New York  10019
2. Issuer Name and Ticker or Trading Symbol
   Procept Incorporated
   PRCT
3. IRS or Social Security Number of Reporting Person (Voluntary)
   
4. Statement for Month/Year
   08/97
5. If Amendment, Date of Original (Month/Year)
   
6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   ( ) Director (X) 10% Owner ( ) Officer (give title below) ( ) Other
   (specify below)
   
7. Individual or Joint/Group Filing (Check Applicable Line)
   (X) Form filed by One Reporting Person
   ( ) Form filed by More than One Reporting Person
<TABLE>
<CAPTION>
___________________________________________________________________________________________________________________________________
 Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned                                                 |
___________________________________________________________________________________________________________________________________|
1. Title of Security       |2.    |3.    |4.Securities Acquired (A)         |5.Amount of        |6.Dir |7.Nature of Indirect       |
                           | Transaction |  or Disposed of (D)              |  Securities       |ect   |  Beneficial Ownership     |
                           |      |      |                                  |  Beneficially     |(D)or |                           |
                           |      |    | |                  | A/|           |  Owned at         |Indir |                           |
                           | Date |Code|V|    Amount        | D |    Price  |  End of Month     |ect(I)|                           |
___________________________________________________________________________________________________________________________________|
<S>                        <C>    <C>  <C><C>               <C> <C>         <C>                 <C>    <C>
Common Stock, $.01 par valu|08/22/|J(1)| |3,882,667 (3)     | D |$.46875 (2)|     0             |   D  |                           |
e per share                |97    |    | |                  |   |(3)        |                   |      |                           |
                           |      |    | |                  |   |           |                   |      |                           |
                           |      |    | |                  |   |           |                   |      |                           |

___________________________________________________________________________________________________________________________________|
<CAPTION>
___________________________________________________________________________________________________________________________________
 Table II -- Derivative Securitites Acquired, Disposed of, or Beneficially Owned                                                   |
___________________________________________________________________________________________________________________________________|
1.Title of Derivative |2.Con-  |3.   |4.    |5.Number of De |6.Date Exer|7.Title and Amount  |8.Price|9.Number    |10.|11.Nature of|
  Security            |version |Transaction | rivative Secu |cisable and|  of Underlying     |of Deri|of Deriva   |Dir|Indirect    |
                      |or Exer |     |      | rities Acqui  |Expiration |  Securities        |vative |tive        |ect|Beneficial  |
                      |cise    |     |      | red(A) or Dis |Date(Month/|                    |Secu   |Securities  |(D)|Ownership   |
                      |Price of|     |      | posed of(D)   |Day/Year)  |                    |rity   |Benefi      |or |            |
                      |Deriva- |     |      |               |Date |Expir|                    |       |ficially    |Ind|            |
                      |tive    |     |      |           | A/|Exer-|ation|   Title and Number |       |Owned at    |ire|            |
                      |Secu-   |     |    | |           | D |cisa-|Date |   of Shares        |       |End of      |ct |            |
                      |rity    |Date |Code|V|  Amount   |   |ble  |     |                    |       |Month       |(I)|            |
___________________________________________________________________________________________________________________________________|
<S>                   <C>      <C>   <C>  <C><C>        <C> <C>   <C>   <C>          <C>     <C>     <C>          <C> <C>
- -----------------------------------------------------------------------------------------------------------------------------------|
Series A Convertible P|$.46875(|08/22|J(1)| |18,200     |A  |08/22|N/A  |Common Stock|3,882,6|$100.00|18,200      |D  |            |
referred Stock, par va|3       |/97  |    | |           |   |/97  |     |            |67(3)  |       |            |   |            |
lue $.01 per share    |        |     |    | |           |   |     |     |            |       |       |            |   |            |
- -----------------------------------------------------------------------------------------------------------------------------------|
                      |        |     |    | |           |   |     |     |            |       |       |            |   |            |
___________________________________________________________________________________________________________________________________|
</TABLE>
Explanation  of  Responses:
(1)  Pursuant to a  securities  purchase  agreement,  dated as of June 30, 1997,
between the Reporting Person,  the Aries Domestic Fund, L.P. and the Issuer (the
"Purchase  Agreement"),  since the approval by the stockholders of the Issuer of
an amendment to the Issuer's  Certificate of  Incorporation  authorizing  "blank
check"  preferred  stock,  the Reporting  Person  elected to put (the "Put") its
3,882,667  shares of Common Stock purchased under the Purchase  Agreement to the
Issuer for Series A Convertible Preferred Stock.
(2) Pursuant to the Put, in exchange for the shares of Common Stock  reported on
Table I, the  Reporting  Person  received  the  shares of  Series A  Convertible
Preferred Stock reported on Table II.
(3) Upon the  earliest of (i) the approval by the holders of Common Stock of the
Issuer  of  the  transactions   contemplated  by  the  Purchase  Agreement  (the
"Transactions") that are required by Rule 4460(i) of the National Association of
Securities  Dealers'  Marketplace  Rules,  (ii) any  event  which  renders  such
stockholder  approval  unnecessary or which renders such Rule  inapplicable  and
(iii)  September 30, 1997,  in light of the Put, the  Reporting  Person shall no
longer be entitled  to a  distribution  of  additional  shares of Common  Stock,
however, the conversion price of the Series A Convertible  Preferred Stock shall
be adjusted to equal the lesser of $.29 and 50% of various market-based prices.

SIGNATURE OF REPORTING PERSON
/s/Lindsay A. Rosenwald, M.D.
- -----------------------------
Lindsay A. Rosenwald, M.D., President
Paramount Capital Asset Management, Investment Manager
The Aries Trust
DATE
09/09/97


<PAGE>

                                  Attachment A


        Reporting Person:           The Aries Trust
        Issuer:                     Procept Incorporated (PRCT)
        Statement For:              August/1997

        Paramount Capital Asset Management,  Inc. ("Paramount"),  the Investment
Manager to The Aries Trust (the  "Trust"),  is also the  General  Partner of the
Aries Domestic Fund (the "Partnership"),  a Delaware limited partnership,  which
also owns  securities  of the Issuer.  Lindsay A.  Rosenwald,  M.D., is the sole
shareholder  of  Paramount.  Paramount  and Dr.  Rosenwald  disclaim  beneficial
ownership of the securities held by the Partnership and the Trust, except to the
extent of their pecuniary interest therein, if any.





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission